Edwards Lifesciences 1 Year or Less decreased by 16.5% to $39.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 26.2%, from $53.00M to $39.10M.
Higher amounts indicate greater near-term liquidity and potential for reinvestment at current market rates.
Represents the contractual maturity or expected cash flow timing of held-to-maturity debt securities falling within the...
Standard liquidity and maturity schedule disclosure for banks.
other_held_to_maturity_securities_debt_maturities_next_r_6f7830| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.00M | $83.00M | $160.00M | $62.50M | $118.50M | $23.50M | $26.30M | $28.00M | $56.00M | $53.40M | $50.50M | $53.00M | $44.70M | $46.80M | $39.10M |
| QoQ Change | — | +137.1% | +92.8% | -60.9% | +89.6% | -80.2% | +11.9% | +6.5% | +100.0% | -4.6% | -5.4% | +5.0% | -15.7% | +4.7% | -16.5% |
| YoY Change | — | — | — | +78.6% | +42.8% | -85.3% | -57.9% | -76.4% | +138.3% | +103.0% | +80.4% | -5.4% | -16.3% | -7.3% | -26.2% |